69 related articles for article (PubMed ID: 17827013)
1. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.
Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
Tao ZF; Li G; Tong Y; Chen Z; Merta P; Kovar P; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Aug; 17(15):4308-15. PubMed ID: 17544271
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.
Li G; Hasvold LA; Tao ZF; Wang GT; Gwaltney SL; Patel J; Kovar P; Credo RB; Chen Z; Zhang H; Park C; Sham HL; Sowin T; Rosenberg SH; Lin NH
Bioorg Med Chem Lett; 2006 Apr; 16(8):2293-8. PubMed ID: 16446090
[TBL] [Abstract][Full Text] [Related]
6. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH
J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116
[TBL] [Abstract][Full Text] [Related]
7. Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Tao ZF; Chen Z; Bui MH; Kovar P; Johnson E; Bouska J; Zhang H; Rosenberg S; Sowin T; Lin NH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6593-601. PubMed ID: 17935989
[TBL] [Abstract][Full Text] [Related]
8. Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
Fanton CP; Rowe MW; Moler EJ; Ison-Dugenny M; De Long SK; Rendahl K; Shao Y; Slabiak T; Gesner TG; MacKichan ML
J Biomol Screen; 2006 Oct; 11(7):792-806. PubMed ID: 17035625
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.
Oza V; Ashwell S; Brassil P; Breed J; Deng C; Ezhuthachan J; Haye H; Horn C; Janetka J; Lyne P; Newcombe N; Otterbien L; Pass M; Read J; Roswell S; Su M; Toader D; Yu D; Yu Y; Valentine A; Webborn P; White A; Zabludoff S; Zheng X
Bioorg Med Chem Lett; 2010 Sep; 20(17):5133-8. PubMed ID: 20673630
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors.
Lin NH; Xia P; Kovar P; Park C; Chen Z; Zhang H; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2006 Jan; 16(2):421-6. PubMed ID: 16242328
[TBL] [Abstract][Full Text] [Related]
11. Identification of inhibitors of checkpoint kinase 1 through template screening.
Matthews TP; Klair S; Burns S; Boxall K; Cherry M; Fisher M; Westwood IM; Walton MI; McHardy T; Cheung KM; Van Montfort R; Williams D; Aherne GW; Garrett MD; Reader J; Collins I
J Med Chem; 2009 Aug; 52(15):4810-9. PubMed ID: 19572549
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors.
Gomha SM; Abdulla MM; Abou-Seri SM
Eur J Med Chem; 2015 Mar; 92():459-70. PubMed ID: 25594740
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases.
Smaill JB; Lee HH; Palmer BD; Thompson AM; Squire CJ; Baker EN; Booth RJ; Kraker A; Hook K; Denny WA
Bioorg Med Chem Lett; 2008 Feb; 18(3):929-33. PubMed ID: 18191399
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of selenophene derivatives as novel CHK1 inhibitors.
Hong PC; Chen LJ; Lai TY; Yang HY; Chiang SJ; Lu YY; Tsai PK; Hsu HY; Wei WY; Liao CB
Bioorg Med Chem Lett; 2010 Sep; 20(17):5065-8. PubMed ID: 20674356
[TBL] [Abstract][Full Text] [Related]
17. Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.
Tong L; Song P; Jiang K; Xu L; Jin T; Wang P; Hu X; Fang S; Gao A; Zhou Y; Liu T; Li J; Hu Y
Eur J Med Chem; 2019 Jul; 173():44-62. PubMed ID: 30986571
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
Osborne JD; Matthews TP; McHardy T; Proisy N; Cheung KM; Lainchbury M; Brown N; Walton MI; Eve PD; Boxall KJ; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Jamin Y; Robinson SP; Westwood IM; van Montfort RL; Leonard PM; Lamers MB; Reader JC; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2016 Jun; 59(11):5221-37. PubMed ID: 27167172
[TBL] [Abstract][Full Text] [Related]
19. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.
Nathan Tumey L; Boschelli DH; Lee J; Chaudhary D
Bioorg Med Chem Lett; 2008 Aug; 18(15):4420-3. PubMed ID: 18606543
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
